Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Equity Average (2022 - 2026)

Zentalis Pharmaceuticals has reported Equity Average over the past 5 years, most recently at $199.4 million for Q1 2026.

  • For Q1 2026, Equity Average fell 36.94% year-over-year to $199.4 million; the TTM value through Mar 2026 reached $199.4 million, down 36.94%, while the annual FY2025 figure was $276.7 million, 28.55% down from the prior year.
  • Equity Average for Q1 2026 was $199.4 million at Zentalis Pharmaceuticals, down from $234.5 million in the prior quarter.
  • Over five years, Equity Average peaked at $502.6 million in Q3 2023 and troughed at $199.4 million in Q1 2026.
  • A 5-year average of $372.0 million and a median of $394.2 million in 2022 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: rose 20.52% in 2023 and later crashed 36.94% in 2026.
  • Year by year, Equity Average stood at $431.4 million in 2022, then grew by 6.54% to $459.6 million in 2023, then dropped by 24.77% to $345.8 million in 2024, then crashed by 32.17% to $234.5 million in 2025, then dropped by 14.96% to $199.4 million in 2026.
  • Business Quant data shows Equity Average for ZNTL at $199.4 million in Q1 2026, $234.5 million in Q4 2025, and $263.7 million in Q3 2025.